Transcription factor Growth factor independence 1 (Gfi1) is required for multilineage blood cell development, from stem and progenitor cells to differentiated lymphoid and myeloid cells. Gfi1 expression is rapidly induced by cytokines that control both the adaptive and innate immune systems. Gfi1 itself represses the expression of genes implicated in cell survival, proliferation and differentiation. Changes in Gfi1 expression and function have not only been implicated in neutropenia, allergy, autoimmunity and hyperinflammatory responses, but also in lymphoma and more recently in the development of leukemia. In this study, we review how Gfi1 and its paralogue Gfi1b control the development of blood cells, discuss how changes in Gfi1 and Gfi1b function contribute to hematological disease and report on the molecular function of these proteins.
Introduction
Growth factor independence 1 (Gfi1) was originally identified as the target gene of an insertion locus of the Moloney murine leukemia virus in an in vitro screen for factors that promote the progression of a leukemia T-cell line to interleukin (IL)-2-independent growth. Following its discovery, a paralogue, Gfi1b, was also identified. After extensive research, it is now known that both Gfi1 and Gfi1b are transcription factors that have a crucial role in hematopoiesis. Mouse studies have shown that Gfi1 is implicated in the development and function of hematopoietic stem cells (HSCs), B and T cells, dendritic cells, granulocytes and macrophages, whereas Gfi1b is essential for megakaryocytic and erythroid development. In this study, we discuss how Gfi1 and Gfi1b regulate gene expression. In addition, we review the stages of hematopoiesis during which Gfi1 and Gfi1b are implicated and how the loss of their function contributes to hematological disease.
Molecular function of Gfi1 and Gfi1b

Structure and expression regulation of Gfi1 and Gfi1b proteins
The human Gfi1 and Gfi1b genes encode for 422 and 330 amino-acid transcription factors, respectively. At the N terminus they contain a small conserved SNAG (Snail/Gfi1) domain that is also present in other transcriptional repressors (Figure 1 ). [1] [2] [3] [4] The SNAG domain serves as an interaction domain to recruit proteins that modify histones. 5 At the C terminus both proteins contain six C 2 H 2 -type zinc fingers of which zinc fingers 3-5 are essential for DNA binding. 2, 6, 7 Between the SNAG and zinc finger domains, there is an intermediate domain that binds proteins implicated in transcriptional regulation, RNA splicing and protein modifications ( Figure 1 ). More than 89% of the SNAG and zinc finger domains are identical in Gfi1 and Gfi1b, whereas the intermediate region only shows low similarity (39%) at the protein level. Despite these differences, the insertion of Gfi1b coding sequences in the Gfi1 gene locus almost completely rescued the hematopoietic phenotypes observed in Gfi1-null mice. 8 This strongly suggests that the proteins exert similar molecular effects. However, a nonhematopoietic phenotype, loss of hearing, caused by a Gfi1 deficiency was not rescued by inserting Gfi1b in the Gfi1 gene locus, indicating that in certain other tissues these proteins function in a different way. 8 Besides in inner ear development, Gfi1 also has a role in gut 9 and lung 10-12 development. Currently, it is unknown whether Gfi1b also has a role in the development of nonhematopoietic tissues. Despite their similar molecular function in hematopoiesis, loss of either Gfi1 or Gfi1b results in very different, nonoverlapping hematopoietic phenotypes. This may in part be caused by the tissue-specific expression of these genes.
Because Gfi1 and Gfi1b are so important in normal hematopoietic development it is important to determine how expression of these genes is regulated. The signaling pathways and transcription factors that regulate Gfi1 and Gfi1b gene expression are only just emerging (Table 1) . In many hematopoietic subsets, the expression of the Gfi1 and Gfi1b genes can be autoregulated by the Gfi1 and Gfi1b proteins themselves. [13] [14] [15] Gfi1 may control the expression of the Gfi1b gene and vice versa, [16] [17] [18] although the biological relevance of this crossregulation is poorly understood as both proteins are expressed in certain cell types. Gfi1 and Gfi1b gene expression is co-regulated by other transcription factors such as Ajuba 19 and Ikaros 20 for Gfi1 and GATA1, NF-Y, Oct1 and HMGB2 for Gfi1b. 15, 17, 21 Gfi1 protein expression is also regulated by microRNAs. 22 Finally, Gfi1 expression is also regulated at the protein level through ubiquitin-proteasome-mediated degradation. 23, 24 Expression of Gfi1 and Gfi1b is therefore tightly regulated at multiple levels. When necessary, these extensive regulatory mechanisms allow for rapid induction or repression of Gfi1-mediated gene regulation.
Gfi1 and Gfi1b in transcriptional regulation, RNA splicing and signaling DNA-sequence-specific transcription factors are important regulators of gene expression. They recruit proteins that modify DNA or DNA-bound histones to make the chromatin accessible or inaccessible for active gene transcription. 25 Gfi1 and Gfi1b bind DNA and suppress gene expression through the recruitment of histone deacetylases and (de)methylases. In addition to proteins that directly modify histones, a series of corepressors known to contribute to histone deacetylation and (de)-methylation interact with Gfi1 and Gfi1b (Figures 1 and 2a) . 19, [26] [27] [28] Together these complexes remove transcription-promoting histone modifications and apply repression marks to prevent transcription (Figures 1 and 2) . 5, 15, 26, 27, [29] [30] [31] However, it should be noted that examples have been reported in which Gfi1 and Gfi1b can activate gene expression. 15, 18, 29, 32 Gfi1 and Gfi1b also interact physically with other transcription factors through their zinc fingers to co-regulate gene expression (Figures 1  and 2) . 17, 29, [33] [34] [35] [36] For example, Gfi1 interacts directly with ETS1 to repress the Bax gene through adjacent DNA binding sites.
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Gfi1 may also mediate repression independently of DNA binding through interactions with the transcription factors Miz-1 and Pu. 1. 34,35 Similarly, Gfi1b controls the activity of the transcription factor GATA1 through direct protein-protein interactions on the DNA. 17, 37 Apart from transcription regulation, Gfi1 also regulates protein expression at another level. Gfi1 mediates alternative splicing of CD45 transcripts and thereby controls T-cell receptor signaling. 38 Gfi1 also controls posttranslational protein modifications. This is achieved through a direct interaction with PIAS3, an inhibitor of STAT3 signaling. 39 As a consequence of binding to Gfi1, the interaction between PIAS3 and STAT3 is impaired allowing STAT3 to function as a transcriptional activator. PIAS3 can control gene expression through SUMOylation of transcriptional regulators. 40 So far, SUMOylation of Gfi1 has not been reported. Interestingly, a recent study showed that binding of the co-repressor protein CoREST1 to SUMO-conjugated proteins is required for repression. 41 As Gfi1 binds both CoREST1 and PIAS3, it is tempting to speculate that Gfi1 might recruit PIAS3 to facilitate SUMOylation of Gfi1 bound proteins (or itself). And this may be important for the recruitment of CoREST1 to repress gene transcription. If this hypothesis turns out to be true, this would add yet another level of control to Gfi1-mediated gene repression.
Biological roles of Gfi1 and Gfi1b
Gfi1 preserves hematopoietic stem cell integrity Hematopoietic stem cells are quiescent cells that have the unique capability of unlimited self-renewal. There is much interest in identifying factors that control self-renewal, quiescence and differentiation of HSCs because many hematological malignancies arise at the stem cell level. Earlier it has been shown that Gfi1 preserves HSC quiescence (Figure 3) . 42, 43 More recently a function in maintaining HSC quiescence has also been described for the tumor suppressor p53. 44 Mice that lack p53 show increased numbers of HSCs but a decreased proportion of cells that exhibit a quiescent phenotype. Importantly, Gfi1 was identified as one of the p53 target genes in HSCs (Table 1) . Consequently Gfi1 expression is significantly downmodulated in p53-null HSCs, which may in part explain the impaired HSC quiescence observed in p53-null mice. Together, these studies indicate that Gfi1 is part of a network of intrinsic factors that control HSC fate and that Gfi1 is directly regulated by p53 to control the quiescence of HSCs. The location of the reported mutations in Gfi1 (N382S and K403R) 45, 46 is indicated with asterisks. A recent mutational screen studying a large cohort of SCN cases identified potential new Gfi1 mutations (P107A, L400F and R412X). 46 Additional studies are required to determine whether these are real mutations contributing to SCN or whether they represent rare polymorphisms. The SNAG and zinc-finger domains are indicated. Gfi1 and Gfi1b proteins show 90 and 89% identity between the SNAG and zinc-finger domains, respectively. The similarity between the intermediate domains is 39%. The minimally required Gfi1 domain for the interaction with interacting partners is indicated with horizontal arrows. Blue and red shaded areas represent chromatin-modifying enzymes and transcription factors, respectively. All Gfi1 and Gfi1b transcription factor interactions occur through the zinc fingers. Nonshaded areas represent other proteins. Gfi1b interacts with many Gfi1 binding partners. Gfi1b also interacts with the histone methyltransferase SUV39H1 and GATA1. Gfi1b is also part of a complex that contains several other transcription factors. 17, 31, 36 Gfi1 in neutropenia, myeloid leukemia and hyperinflammatory responses
Possibly one of the most profound phenotypes of the loss of Gfi1 function is found in neutrophil development. In humans, rare inherited mutations in Gfi1 have been shown to cause severe congenital neutropenia (SCN) and nonimmune chronic idiopathic neutropenia of adults ( Figure 3) . 45, 46 In addition, diminished Gfi1 expression may contribute to the development of neutrophil-specific granule deficiency by causing reduced levels of secondary granule protein expression. 32 A condition similar to human SCN is encountered in mice that lack Gfi1 or that express the mutated form of Gfi1 found in a SCN patient. [47] [48] [49] This strongly suggests that the mutated Gfi1 form that causes SCN, functions in a dominant-negative manner over wild-type Gfi1. In the myeloid compartment, Gfi1 is part of a regulatory network that determines lineage fate decision between granulocyte and monocyte/macrophage development. In this compartment, Gfi1 antagonizes the function of the transcription factor Pu. 1 . Pu.1 promotes monocytic differentiation, whereas Gfi1 enhances granulocytic differentiation. Gfi1 and Pu.1 inhibit each other's function by competing for DNA binding in promoters of target genes. 20, 50 However, Gfi1 also inhibits Pu.1 by direct repression of the Pu.1 gene 20 and by counteracting Pu.1 function through a protein-protein interaction. 35 In contrast, Pu.1 enhances the expression of transcription factors that inhibit Gfi1 gene expression. 50 Thus, loss of Gfi1 function in SCN patients may tip the balance toward Pu.1 mediated monocytic development explaining the neutropenia. This also implies that genes that are normally repressed by Gfi1 may be induced in patients with Gfi1 mutations. ELA2, encoding neutrophil elastase, is a Gfi1 target gene. 45, 51 In line with these findings, increased neutrophil elastase expression and activity have been observed in myeloid colonies and in peripheral blood cells of individuals with a Gfi1 mutation. 45 Currently, it is unclear whether increased neutrophil elastase activity, as a result of loss of Gfi1 function, contributes to neutropenia. The fact that ELA2 mutations cause congenital neutropenia 52 warrants further functional studies to determine whether an increase in wild-type neutrophil elastase expression contributes to neutropenia in patients with Gfi1 mutations. Apart from ELA2, the expression of genes implicated in myelopoiesis has been shown to be deregulated as a consequence of Gfi1 loss of function. Examples include colony-stimulating factor 1 (CSF1) and RAS guanyl-releasing protein (RasGRP1). CSF1 is a cytokine that promotes monocytic and represses granulocytic development. In myeloid precursor cells CSF1 is repressed by Gfi1. CSF1 is overexpressed when Gfi1-mediated repression is lacking both in SCN patient cells and in murine bone marrow cells that lack functional Gfi1. 49 In mice that expressed the SCN-related mutated form of Gfi1, neutrophilic differentiation was partly restored in a CSF1-null background or on inhibition of CSF1 signaling. This suggests that a lack of functional Gfi1 may, at least in part, cause defective granulocytic differentiation because CSF1 is overexpressed. A recent study indicates that Gfi1 actively promotes neutrophilic differentiation by enhancing RasGRP1 expression. 53 RasGRP1 augments granulocyte colonystimulating factor-mediated neutrophilic differentiation. In Gfi1-null cells, RasGRP1 expression is reduced. RasGRP1 expression in Gfi1-null cells partly restores neutrophilic differentiation. It is remarkable that in Gfi1-null cells RasGRP1 is lacking and that Gfi1 has a positive effect on RasGRP1 gene expression. Whether Gfi1 activates RasGRP1 gene expression directly or indirectly by repressing an inhibitor of RasGRP1 remains to be determined. A recent study suggested that in addition to protein encoding genes, Gfi1 can directly repress murine microRNAs that promote monocytic differentiation and repress granulocytic differentiation. The expression of these microRNAs is induced when Gfi1 function is defective. 54 Together, these studies indicate that Gfi1 represses genes that favor monocytic differentiation and promotes expression of genes that enhance granulocytic differentiation. This is consistent with the observation that monocyte numbers are increased in SCN patients that carry a mutation in the Gfi1 gene. 45 In addition to the presence of neutropenia, an accumulation of an aberrant population of immature myeloid progenitors is observed in SCN patients with Gfi1 mutations and Gfi1-null 
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Target Gene Target Gene mice. 47, 48, 55 Inhibitor of DNA binding 2 (Id2) is a Gfi1 target gene and Id2 expression is elevated in myeloid progenitors from Gfi1-null mice. 56 Reducing Id2 levels in a Gfi1-null background partially restored the expansion of immature myeloid cells. Thus, the increase of Id2 levels in Gfi1-null cells may have a role in the expansion of the atypical immature myeloid population. The increase of atypical immature myeloid cells in Gfi1-null mice is also diminished in a homeobox A9 (HoxA9) hemizygous and null background. This indicates that the expansion of the immature myeloid population in Gfi1-null mice also depends on HoxA9 induction. 55 Indeed, Gfi1 directly represses HoxA9 gene expression and this repression is lost in cells lacking functional Gfi1 (Table 1) . In line with the finding that HoxA9 overexpression triggers myeloid malignancies in mice, 57, 58 Gfi1-null mice show features that are reminiscent of acute myeloid leukemia. They show uncontrolled proliferation of myeloid progenitors that are blocked in their differentiation. A recent study showed that lack of Gfi1 induces progression of mutant K-ras-induced myeloproliferative disease toward acute myeloid leukemia. This suggests that diminished Gfi1 expression may be associated with myeloid transformation. Low expression of Gfi1 has been found in subtypes of patients with myelodysplastic syndromes. 59 In contrast, elevated expression of Gfi1 has been reported in patients with chronic myeloid leukemia, 60 and large variations of Gfi1 expression were detected in different acute myeloid leukemia subtypes. 61 It will therefore be important to study whether an aberrant Gfi1 expression contributes to the development of human myeloid malignancies. Recently, a polymorphism in Gfi1 that predisposes to acute myeloid leukemia development in humans has been found. 62 This Gfi1 variant, which is characterized by the substitution of a serine by an asparagine at amino-acid position 36, does not affect its repressive properties, but does cause the protein to adopt an aberrant nuclear localization. The altered localization may imply that the variant form of Gfi1 is part of other protein complexes as compared with the common form of Gfi1. How this predisposes to leukemia formation will remain a subject for further study. Together, the findings summarized in this study suggest a role for Gfi1 in myeloid leukemia.
As discussed above, Gfi1 has an important developmental role in myeloid progenitor cells by controlling their proliferation and differentiation. In mature end-stage granulocytes the protein is expressed at low levels. 23 It has been shown that in these cells Gfi1 cooperates with C/EBPe to control expression of genes that are implicated in terminal differentiation. 32 Gfi1 is not required for the differentiation of myeloid progenitors toward monocytes. However, in CD14 þ monocytes, the Gfi1 protein is expressed and binds to genes required for granulocytic differentiation and function (Table 1) . 23 This suggests that Gfi1 may repress genes that are implicated in granulocytic development in monocytes.
Gfi1 also has a role in macrophages and dendritic cells. Gfi1 shows dynamic changes in expression during the development Figure 3 Gfi1 and Gfi1b have a broad role in hematopoiesis. Gfi1 is an essential transcription factor that is implicated in various stages of hematopoiesis in both the lymphoid (light blue shading) and the myeloid (dark blue) lineage. Gfi1 is required for either proliferation (green curved arrows) or differentiation from one hematopoietic subset toward another (straight green arrows). Gfi1 inhibits differentiation (straight red arrow) or inhibits proliferation (red curved arrow). Gfi1b is essential for megakaryopoiesis and erythropoiesis (red shading) as indicated by the dashed green lines. HSC, hematopoietic stem cell; NK, natural killer cell; CLP, common lymphoid progenitor; CMP, common myeloid progenitor; MEP, megakaryocyte-erythroid progenitor; GMP, granulocyte-macrophage progenitor; Th, T helper cell; iTreg, inducible regulatory T cell.
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of not only myeloid but also of plasmacytoid DCs (mDCs and pDCs). 63 Possibly as a result of defective STAT3 signaling (Table 1) , 39, 63 Gfi1-null mice have lower mDC and pDC numbers, show impaired DC maturation and their mDCs show increased cytokine production. In vitro differentiation experiments show that Gfi1-null progenitor cells are unable to develop into mDCs, but instead develop into macrophages (Figure 3) . 63 In mature macrophages, Gfi1 inhibits the production of proinflammatory cytokines after exposure to Gram-negative bacteria or to the bacterial endotoxin lipopolysaccharide. 10, 11, 47 As a result of the uncontrolled release of these cytokines, 10 Gfi1-null mice have sepsis and rapidly die on infection ( Figure 3 , Table 1 ).
Gfi1 in T-cell development, allergy and lymphoma
In addition to the myeloid lineage, Gfi1 is also implicated in lymphoid development. Gfi1 is required at various stages during T-cell development, ranging from early to common lymphoid progenitors to mature functional T cells. Patients who have SCN because of mutations in the Gfi1 gene show decreased absolute numbers of T cells. 45 These findings are similar to those observed in Gfi1-null mice (Figure 3a , Table 1) . 47, 48, 64, 65 Following their activation, T cells can differentiate into cytokine expressing CD4
þ or cytotoxic CD8 þ T cells. Depending on the type of stimulus, naive CD4 þ T cells differentiate into various cytokine expressing T-cell subsets including T helper (Th) 1, 2 and 17 as well as inducible regulatory T cells (iTregs) (Figure 3) . Th1 cell expansion is only mildly affected on loss of Gfi1 function, whereas Th2 cell expansion is severely impaired. 66, 67 In contrast to the requirement of Gfi1 for the expansion of Th2 cells, Gfi1 suppresses the formation of Th17 cells and iTreg cells. [68] [69] [70] Like Th cells, iTregs are derived from CD4 þ T cells, but in contrast to Th cells, iTregs suppress immune responses. 71 Because Gfi1 inhibits the expansion of iTregs, mice that lack Gfi1 have more iTregs. 70 In line with this increase in iTreg cell numbers, Gfi1-null mice show a delayed onset of experimental allergic encephalitis.
Naive CD8 þ T cells develop into cytotoxic effector T cells on activation. The activation of these cells is associated with downmodulation of IL-7Ra expression. 72 Cytotoxic effector T cells expand following infection, but as soon as the infection ceases, the majority of these cells undergo apoptosis. Small subsets of CD8 þ T cells with high IL-7Ra expression remain alive to form memory T cells that can be reactivated on recurrent infections. Gfi1 is required for sustained IL-7Ra repression in late-stage cytotoxic effector T cells and loss of Gfi1 results in increased IL-7Ra expression in these cells (Table 1) . 73 As a result, Gfi1-null mice show a relative increase in phenotypically defined memory CD8 þ T cells. 74 The finding that Gfi1-null mice are able to raise CD8 þ T-cell-mediated antiviral responses shows that these cells are indeed functional. On prolonged viral infection, Gfi1-null mice exhibit increased numbers of virus-specific CD8 þ T cells compared with wildtype mice. 74 Whether this is because of decreased apoptosis as a consequence of high IL-7Ra expression or because of increased viral loads that are observed in Gfi1-null mice remains to be elucidated.
The effects of Gfi1 on the expansion and development of different T-cell subsets have been attributed to differential expression of growth factors, their receptors and antiapoptotic genes (Table 1) . Conversely, the expression of the Gfi1 gene itself is regulated by antigens and growth factors. For example, Gfi1 expression is induced following Th2 cell activation by antigens and further stimulated by cytokines implicated in Th2 cell expansion. 67, 70 Gfi1 subsequently suppresses genes that are required for the development of Th17 and iTreg cells. 70 Although some genes, like IL-17, are directly repressed by Gfi1, others are repressed indirectly. 75 In contrast to the activation following antigen exposure, Gfi1 expression is downmodulated by transforming growth factor-b that promotes Th17 and iTreg development. 70 As a consequence, genes essential for the development of these T-cell subsets are not repressed by Gfi1 (Table 1) .
As discussed above, Gfi1 positively regulates proliferation of various T-cell subsets. The relevance of these findings is underscored by the fact that Gfi1 is one of the most frequently activated genes in retrovirally induced lymphomas in mice. [76] [77] [78] [79] Gfi1 overexpression inhibits apoptosis through repression of proapoptotic genes. 80 In addition, Gfi1 enhances cell-cycle entrance through inhibition of negative regulators of the cell cycle. 81 Thus, lack of Gfi1 contributes to progression of myeloid leukemia in murine models, whereas forced Gfi1 expression induces lymphomas. This indicates that depending on the cellular context, Gfi1 functions as a tumor suppressor or oncogene. 82 Gfi1 can also cooperate with other oncogenes in lymphomagenesis. This is based on the fact that the time to tumor development on Gfi1 overexpression is significantly shortened when mice express other oncogenes like Myc and Pim. [83] [84] [85] Gfi1 may exert p53-dependent effects to limit the proliferation of HSC. 44 These functions are likely not operational in Gfi1-induced lymphoma. Indeed, a recent study suggests that Gfi1 can function independently of p53 tumor suppressor pathways because integrations in the Gfi1 locus in virally induced T-cell lymphomas were as frequent in p53-null mice as in wild-type mice. 79 In conclusion, Gfi1 is essential for the development of early T-cell subsets, and is an important regulator of adaptive immune responses by both enhancing and inhibiting different mature T-cell subsets. Furthermore aberrant expression of Gfi1 contributes to lymphoma development.
Gfi1 in B-cell development and autoimmunity
In the bone marrow, common lymphoid progenitors develop through distinct progenitor B-cell populations toward mature B cells. Following their activation, B cells secrete specific antibodies. Gfi1 is expressed in early B cells and expression decreases as B cells mature. 13, 86 Mice that lack Gfi1 show diminished immature B-cell populations. 48 In vitro B-cell differentiation and proliferation of Gfi1-null cells is severely impaired, but can be rescued by ectopic expression of Gfi1. Conversely, forced expression of Gfi1 in multipotent progenitor cells increases the number of developing B cells. 20 Comparable to its function in myeloid development in which Gfi1 favors neutrophil over macrophage development, 50 Gfi1 expression favors B-cell development over myeloid development by inhibiting the transcription factor Pu. 1. 20 Hemizygous loss of Pu.1 in a Gfi1-null background can rescue B-cell development. Similar to the findings in myeloid progenitor cells, increased expression of the Gfi1 target gene Id2 was also observed in B-cell progenitors of Gfi1-null mice. 56 Id2 antagonizes the activity of transcription factors that are crucial for B-cell development, including Pax5 and E2A. 87 The increased expression of Id2 in Gfi1-null mice may therefore compromise B-cell development. Indeed, hemizygous loss of Id2 or knockdown of Id2 expression partially rescued B-cell development in Gfi1-null mice. These data define Gfi1 as an important transcription factor that determines lineage fate decisions at the progenitor level by regulating transcriptional programs that control B-cell development.
IL-7 is a crucial factor for B-cell differentiation and proliferation. In Gfi1-null cells IL-7-mediated signaling is disturbed. This is potentially caused by lack of Gfi1-mediated repression of inhibitors of IL-7 signaling pathways (Table 1) . IL-7Ra signaling is hampered by inhibition of STAT5 signaling in Gfi1-null cells, possibly as a result of increased expression of the STAT inhibitor SOCS3. 86 Furthermore, as discussed above, Gfi1 directly represses IL-7Ra expression. Consequently, IL-7Ra expression is high in Gfi1-null B cells. As high IL-7Ra levels may inhibit B-cell development, 88 the increased levels of IL-7Ra may also contribute to the impaired B-cell development that is found in Gfi1-null cells.
In Gfi1-null mice, peripheral B cells show an aberrant hyperactivated phenotype and some mice show plasmacytosis. 48, 86 Following antigen stimulation of B cells, Gfi1 expression is induced (Table 1) . Gfi1-null B cells show enhanced transforming growth factor-b production, a factor important for immunoglobulin secretion. 89 As a result, the secretion of several immunoglobulin G is increased. 89, 90 In line with the disturbed B-cell function, Gfi1-null mice have been reported to develop a wide spectrum of autoimmune diseases including eczema and colitis. 90 Gfi1b in erythroid and megakaryocytic development and in leukemia and lymphoma
The closely related paralogue of Gfi1, Gfi1b is highly expressed in erythroid and megakaryocytic precursors. Gfi1 expression is undetectable in these cells. The fact that Gfi1b has been shown to be essential for the development of the erythroid and megakaryocytic lineages is consistent with these findings. Mice that lack Gfi1b die during embryogenesis because of lack of definitive erythropoiesis, thus preventing a detailed analysis of any other hematopoietic stages in which Gfi1b might be important. To circumvent the problem of embryonic lethality, Gfi1b has been overexpressed and silenced in various immature precursor subsets. This showed that silencing of Gfi1b in CD34 þ cells resulted in decreased proliferation of progenitor cells and inhibition of differentiation toward erythroblasts and megakaryocytes. 91 In contrast, forced Gfi1b expression in human CD34
þ cells enhanced the expansion of immature erythroblasts, but did not induce erythroid commitment and inhibited differentiation beyond the proerythroblast stage. 92 However, enforced Gfi1b expression in more differentiated CD36 þ /GPA À erythroid precursors inhibited proliferation and induced erythroid differentiation. 93 This indicates that during erythropoiesis, Gfi1b triggers opposing phenotypes depending on the developmental stage. In immature CD34 þ cells, Gfi1 expression is sustained on loss of Gfi1b expression. Despite the expression of Gfi1, erythropoiesis and megakaryopoiesis are not rescued. 91 This suggests that Gfi1 cannot compensate for the effects of loss of Gfi1b in erythroid development.
Owing to loss of function, models for Gfi1b have been reported only very recently; the molecular mechanism through which Gfi1b controls erythropoiesis and megakaryopoiesis is poorly understood. Recently it has been stated that Gfi1b may control erythropoiesis by directly repressing the expression of the transforming growth factor-b receptor III gene, and thereby regulating transforming growth factor-b signaling (Table 1) . 91 Gfi1b is also expressed in common myeloid progenitors and in specific B-and T-cell subsets. 94 Whether Gfi1b is essential for the development of these lineages in vivo is currently unknown.
Although the contribution of the loss of function of Gfi1b to the formation of leukemia has not been studied in murine models, Gfi1b has been implicated in chronic myeloid leukemia in humans. 95 This disease is characterized by the constitutively active tyrosine kinase BCR-ABL. Inhibition of this kinase with the drug imatinib results in downregulation of antiapoptotic Bcl-XL that contributes to apoptosis of the leukemic cells. Following treatment with imatinib, Gfi1b is induced and triggers the downmodulation of the antiapoptotic Bcl-XL gene in chronic myeloid leukemia cells. 37, 95 The relevance of the Gfi1b induction was underscored by the fact that Gfi1b silencing inhibited imatinib-induced apoptosis. As in leukemia, downregulation of Gfi1b may also contribute to lymphoma development. Gfi1b gene expression is directly regulated by the tumor suppressor E2A. In lymphomas with loss of E2A function, Gfi1b expression is lost. However, forced Gfi1b expression inhibited proliferation and survival of lymphoma cells. 96 In conclusion, Gfi1b is essential for erythroid and megakaryocytic development and its induction triggers apoptosis of chronic myeloid leukemia and lymphoma cells.
Conclusion
Gfi1 and Gfi1b function both upstream and downstream of cytokine signaling processes, defining these proteins as important factors that connect extracellular signals to intracellular mechanisms. Both proteins have a crucial role in lineage fate decisions. Whereas Gfi1b is essential for erythroid and megakaryocytic differentiation, Gfi1 is implicated in the development of almost all other blood cell types. In addition, proliferation of different hematopoietic subsets as well as lymphocyte activation is regulated by Gfi1. To understand fully how Gfi1 and Gfi1b control hematopoiesis, it will be important to identify more relevant target genes. Similarly, it will be important to determine which co-factors are used by Gfi1 and Gfi1b in the various hematopoietic subsets. The control of proliferation, differentiation and survival of blood cells by Gfi1 and Gfi1b shows striking functional similarities to a set of other hematopoietic transcription factors. [97] [98] [99] Inherited and acquired mutations in many of these hematopoietic transcription factors cause hematological diseases. As loss of Gfi1/Gfi1b function leads to various different hematological defects in experimental settings, it is warranted to further study their contribution to human hematological disease.
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